Submission Deadline
05 Apr 2024 (Vol 47 , Iss 04 )

Upcoming Publication
31 Mar 2024 (Vol 47 , Iss 03 )

Archive-

Teikyo Medical Journal


Journal ID : TMJ-31-01-2021-10509
Total View : 357

Title : Dialysis Disequilibrium Syndrome: Pathophysiology and Management

Abstract :

Dialysis disequilibrium syndrome (DDS) is defined as a clinical syndrome of neurologic abnormalities seen in patients undergoing hemodialysis. There are several theories that support the mechanism for DDS, such as Urea Transporter and Aquaporins in the brain, reversed urea effect, idiogenic osmole, metabolic and cerebral acidosis mechanism. Dialysis disequilibrium syndrome is a clinical condition diagnosed in patients at risk undergoing hemodialysis. There is no laboratory examination for DSS and is still a diagnosis of exclusion. The main target in the management of DDS is to reduce brain edema and prevent complications.7 If DDS is suspected in a patient, strong consideration should be given to discontinuing dialysis therapy. Patients should always be closely monitored and if any deterioration occurs, stop the hemodialysis immediately. Severe symptoms should improve within 24 hours after dialysis is stopped.

Full article
Journal ID : TMJ-20-01-2021-10507
Total View : 442

Title : Primary Advanced Stage Non-Smoking Human Lung Cancer Peripheral Blood Mononuclear Cells Count

Abstract :

Lung cancer is found to cause the inactivation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells which are mostly found in the peripheral blood mononuclear cells (PBMC) and prevent host resistance to lung cancer growth. Thus, by knowing whether there is a decrease in PBMC count in lung cancer patients, immune cell therapy can be considered to increase host resistance towards lung cancer growth. PBMC samples from 3 lung cancer patients and 3 non-lung cancer patients were taken from Klinik Hayandra database with patient’s informed consent. PBMC were then counted and calculated for their viability and proportion with Trypan Blue Staining. PBMC proportion is significantly lower (p=0.002) in lung cancer patients (402,500) than patients without lung cancer (1,465,000). PBMC viability is significantly lower (p=0.015) in lung cancer patients (95.97%) than control group (98.84%). A significant decrease was found in both PBMC proportion and viability in patients with lung cancer than the control group.

Full article

Journal Visit

Top Visit

Medium Visit

Less Visit

Not Visit

//